Tong Ren Tang Reports Fiscal 2025 Results with Net Profit Attributable to Owners Declining 24.1% to 396 Million Yuan

Stock News

Mar 27

Tong Ren Tang Technologies (01666) announced its annual results for the period ending December 31, 2025. Revenue reached 6.484 billion yuan, representing a decrease of 10.7% compared to the previous year. Net profit attributable to owners of the company was 396 million yuan, down by 24.1% year-on-year. Basic earnings per share were 0.31 yuan, and the company proposed a final dividend of 0.18 yuan per share (including tax). During 2025, the group had 52 products with sales exceeding 5 million yuan, including nine products with sales surpassing 100 million yuan. Among its leading products, the Liuwei Dihuang Pill series saw a sales increase of 20.70% compared to the same period last year, the Xihuang Pill series grew by 19.02%, and the Niuhuang Jiedu series rose by 12.45%. However, sales revenue for the Ganmao Qingre Granules series and the Shengmai Yin Oral Liquid series declined compared to the prior year period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1186940226"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186940226\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186940226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186940226","market":"other","top_or_hot":-1,"title":"Tong Ren Tang Reports Fiscal 2025 Results with Net Profit Attributable to Owners Declining 24.1% to 396 Million Yuan","media":"Stock News","content":"<p>Tong Ren Tang Technologies (01666) announced its annual results for the period ending December 31, 2025. Revenue reached 6.484 billion yuan, representing a decrease of 10.7% compared to the previous year. Net profit attributable to owners of the company was 396 million yuan, down by 24.1% year-on-year. Basic earnings per share were 0.31 yuan, and the company proposed a final dividend of 0.18 yuan per share (including tax). During 2025, the group had 52 products with sales exceeding 5 million yuan, including nine products with sales surpassing 100 million yuan. Among its leading products, the Liuwei Dihuang Pill series saw a sales increase of 20.70% compared to the same period last year, the Xihuang Pill series grew by 19.02%, and the Niuhuang Jiedu series rose by 12.45%. However, sales revenue for the Ganmao Qingre Granules series and the Shengmai Yin Oral Liquid series declined compared to the prior year period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tong Ren Tang Reports Fiscal 2025 Results with Net Profit Attributable to Owners Declining 24.1% to 396 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTong Ren Tang Reports Fiscal 2025 Results with Net Profit Attributable to Owners Declining 24.1% to 396 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-27 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tong Ren Tang Technologies (01666) announced its annual results for the period ending December 31, 2025. Revenue reached 6.484 billion yuan, representing a decrease of 10.7% compared to the previous year. Net profit attributable to owners of the company was 396 million yuan, down by 24.1% year-on-year. Basic earnings per share were 0.31 yuan, and the company proposed a final dividend of 0.18 yuan per share (including tax). During 2025, the group had 52 products with sales exceeding 5 million yuan, including nine products with sales surpassing 100 million yuan. Among its leading products, the Liuwei Dihuang Pill series saw a sales increase of 20.70% compared to the same period last year, the Xihuang Pill series grew by 19.02%, and the Niuhuang Jiedu series rose by 12.45%. However, sales revenue for the Ganmao Qingre Granules series and the Shengmai Yin Oral Liquid series declined compared to the prior year period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1186940226","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186940226","pubTimestamp":1774608137,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tong Ren Tang Technologies (01666) announced its annual results for the period ending December 31, 2025. Revenue reached 6.484 billion yuan, representing a decrease of 10.7% compared to the previous...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1606":"中医药概念","01666":"同仁堂科技","BK1583":"高瓴概念"},"translate_title":"同仁堂公布2025财年业绩归属于所有者的净利润下降24.1%至3.96亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01666":1},"content_text":"Tong Ren Tang Technologies (01666) announced its annual results for the period ending December 31, 2025. Revenue reached 6.484 billion yuan, representing a decrease of 10.7% compared to the previous year. Net profit attributable to owners of the company was 396 million yuan, down by 24.1% year-on-year. Basic earnings per share were 0.31 yuan, and the company proposed a final dividend of 0.18 yuan per share (including tax). During 2025, the group had 52 products with sales exceeding 5 million yuan, including nine products with sales surpassing 100 million yuan. Among its leading products, the Liuwei Dihuang Pill series saw a sales increase of 20.70% compared to the same period last year, the Xihuang Pill series grew by 19.02%, and the Niuhuang Jiedu series rose by 12.45%. However, sales revenue for the Ganmao Qingre Granules series and the Shengmai Yin Oral Liquid series declined compared to the prior year period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}